These results, also presented at the 2015 European Cancer Congress (ECC2015, abstract # 5BA) today, which involve the group of 1,626 patients with a Recurrence Score
between 0 and 10, demonstrated that 99.3 percent of node - negative, estrogen receptor (ER)- positive, human
epidermal growth factor receptor 2 (HER2)- negative patients who met accepted guidelines for recommending chemotherapy in addition to hormonal therapy, had no distant recurrence at five years after treatment with hormonal therapy alone.